

Alicanto Consult as a clinical tool for virtual tumor boards, asynchronous dialogues and referrals across the BILH Cancer Care Network

Andrew C. Lyu, MD¹; Jessica A. Zerillo, MD^{2,4}; David J. Einstein, MD²; Robin Joyce, MD³; Melis Celmen, MHA⁴; Brian Russell, MD¹; Katherine Bloom⁵; Yuri Quintana, PhD⁵

¹Department of Medicine, BIDMC, ²Division of Medical Oncology, BIDMC, ³Division of Hematology and Hematologic Malignancies, BIDMC, ⁴BID Cancer Center, ⁵Division of Clinical Informatics, BIDMC

Introduction/Problem


With the COVID-19 pandemic and limited in-person attendance at meetings, the Division of Hematology/Medical Oncology saw a need to develop and implement a clinical platform that would allow for tumor boards to be conducted virtually. Such a platform required the ability to easily upload, safely store, organize and access clinical data by collaborators across the BILH network.

At the same time, with the growth of the BILH care network, patients have access to a wide variety of care options, ranging from convenient community locations with high-quality care to more specialized quaternary care centers. Within Hematology/Medical Oncology, patients are able to receive care close to home in their communities and have the ability to be referred for specialized care including clinical trials at BIDMC. To provide the best, personalized patient-centered care, patients are often referred from one BILH site to another. Keeping track of patient referrals across a wide variety of EMR systems has been a challenge with the growth of the network.

Aim/Goal

To develop and implement an online platform to allow for virtual tumor boards, efficient, asynchronous clinical discussions and electronic referrals across the BILH cancer care network

Implementation and Design



- Alicanto (<https://www.alicantocloud.com>) - an online platform with tools to support group collaboration, such as web conferencing, document sharing, and asynchronous discussion forums
- Developed by Dr. Yuri Quintana and his team at the BIDMC Division of Clinical Informatics
- Alicanto BIDMC - launched in December 2019, initially to support collaborative work across BILH within Hematology; can be accessed online at <https://www.alicantobidmc.org/> or with a mobile application. <https://apps.apple.com/al/app/alicante-mobile/id1481350682>
- Alicanto Consult – part of Alicanto BIDMC; developed and preliminarily implemented in March 2020 to support virtual tumor boards and “Difficult Cases in Oncology COVID19 Forum”
- In order to support referrals across the BILH Cancer Care Network, a pilot program was launched in January 2021 between BIDMC and BI Plymouth within the hematologic malignancies and genitourinary oncology disease subgroups


- Features and Advantages of Alicanto Consult:**
- Allows users from all BILH sites (regardless of home EMR) to easily submit and review clinical cases via an online interface
 - Ability to upload, securely store, organize and access clinical data via an online web interface or iOS application
 - Workstation notifications via browser while logged into Consult system
 - In-house team development team allows for customization and system modifications to be made rapidly depending on clinical need

Above: Alicanto Consult Web interface

Right: Alicanto iOS mobile application

For more information, contact:

Andrew Lyu, MD, Hospitalist, Division of Medical Oncology; alyu@bidmc.harvard.edu




Alicanto Consult as a clinical tool for virtual tumor boards, asynchronous dialogues and referrals across the BILH Cancer Care Network



Andrew C. Lyu, MD¹; Jessica A. Zerillo, MD^{2,4}; David J. Einstein, MD²; Robin Joyce, MD³; Melis Celmen, MHA⁴; Brian Russell, MD¹; Katherine Bloom⁵; Yuri Quintana, PhD⁵

¹Department of Medicine, BIDMC, ²Division of Medical Oncology, BIDMC, ³Division of Hematology and Hematologic Malignancies, BIDMC, ⁴BID Cancer Center, ⁵Division of Clinical Informatics, BIDMC

Results/Progress to Date





- Total of **612** cases submitted by **62** unique users between January 2020 – October 2021
- Total of **198** users from:
 - BIDMC Medical Oncology
 - BIDMC Hematology and Hematologic Malignancies
 - BILH Cancer Care network:
 - BID-Plymouth
 - BID-Needham
 - BID-Milton
 - AJH
 - MAH
 - Lahey Hospital & Medical Center
 - Beverly Hospital
 - Atrius Health
 - BIDMC Divisions of Radiation Oncology, Radiology, Pathology, Surgical Oncology, Urologic Surgery, Gynecology and more



Submissions by Location

Location	Number	(%)
AJH	6	1.0%
Atrius Health	2	0.3%
Beverly Hospital	1	0.2%
BIDMC Cancer Center	558	91.2%
BID-Milton	1	0.2%
BID-Needham	24	3.9%
BID-Plymouth	2	0.3%
LHMC	8	1.3%
MAH	10	1.6%



Key Points

- Alicanto Consult has allowed clinicians from across the BILH Cancer Care Network to easily submit clinical cases for multidisciplinary review in an online, collaborative environment without the need for in-person meetings during the COVID-19 pandemic
- Through this collaboration, knowledge can be shared and brought to the patient, wherever that patient is being cared for. When appropriate, this collaboration then encourages referrals of patients across BILH sites of care to ensure that patients are receiving the highest quality of care, as close to home as possible
- Alicanto Consult allows for efficient clinical communication, expedient clinical care, and the potential to centralize and organize referrals from across the BILH network

Next Steps

- Platform roll-out to additional disease subgroups interested in utilizing Alicanto Consult for virtual tumor boards
- Enrollment of additional BILH clinical care sites and disease groups to simplify network referrals with the hope of minimizing administrative redundancies and ultimately improving the overall clinical experience for patients across the BILH Cancer Center network.

For more information, contact:

Andrew Lyu, MD, Hospitalist, Division of Medical Oncology; alyu@bidmc.harvard.edu